202 related articles for article (PubMed ID: 35939783)
41. Patient-Reported Outcomes among Multiple Myeloma Patients Treated with Standard of Care Idecabtagene Vicleucel.
Oswald LB; Gudenkauf LM; Li X; De Avila G; Peres LC; Kirtane K; Gonzalez BD; Hoogland AI; Nguyen O; Rodriguez Y; Baz RC; Shain KH; Alsina M; Locke FL; Freeman C; Castaneda Puglianini O; Nishihori T; Liu H; Blue B; Grajales-Cruz A; Jim HSL; Hansen DK
Cancers (Basel); 2023 Sep; 15(19):. PubMed ID: 37835405
[TBL] [Abstract][Full Text] [Related]
42. Next-Generation Chimeric Antigen Receptor T-cells.
Yi D; Gergis M; Hsu J; Yang Y; Bi X; Aljurf M; Gergis U
Hematol Oncol Stem Cell Ther; 2022 Dec; 15(3):117-121. PubMed ID: 36537905
[TBL] [Abstract][Full Text] [Related]
43. Infectious complications in patients with relapsed refractory multiple myeloma after BCMA CAR T-cell therapy.
Kambhampati S; Sheng Y; Huang CY; Bylsma S; Lo M; Kennedy V; Natsuhara K; Martin T; Wolf J; Shah N; Wong SW
Blood Adv; 2022 Apr; 6(7):2045-2054. PubMed ID: 34543400
[TBL] [Abstract][Full Text] [Related]
44. Chimeric antigen receptor T-cells, bispecific antibodies, and antibody-drug conjugates for multiple myeloma: An update.
Lakshman A; Kumar SK
Am J Hematol; 2022 Jan; 97(1):99-118. PubMed ID: 34661922
[TBL] [Abstract][Full Text] [Related]
45. Prolonged hematological toxicity in patients receiving BCMA/CD19 CAR-T-cell therapy for relapsed or refractory multiple myeloma.
Li H; Zhao L; Sun Z; Yao Y; Li L; Wang J; Hua T; Ji S; Wang S; Cheng H; Shi M; Li Z; Zeng L; Wu Q; Qiao J; Chen C; Zheng J; Cao J; Xu K
Front Immunol; 2022; 13():1019548. PubMed ID: 36330523
[TBL] [Abstract][Full Text] [Related]
46. Early Time-to-Tocilizumab after B Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy in Myeloma.
Banerjee R; Marsal J; Huang CY; Lo M; Kambhampati S; Kennedy VE; Arora S; Wolf JL; Martin TG; Wong SW; Shah N
Transplant Cell Ther; 2021 Jun; 27(6):477.e1-477.e7. PubMed ID: 33831353
[TBL] [Abstract][Full Text] [Related]
47. Predictors of cytopenias after treatment with axicabtagene ciloleucel in patients with large B-cell lymphoma.
Panaite L; Wu QV; Voutsinas J; Mullane E; Chow VA; Lynch RC; Ujjani CS; Smith SD; Gopal AK; Poh C; Iovino L; Turtle CJ; Maloney DG; Till BG; Gauthier J; Shadman M
Leuk Lymphoma; 2022 Dec; 63(12):2918-2922. PubMed ID: 35811554
[TBL] [Abstract][Full Text] [Related]
48. [New European approval: Idecabtagene vicleucel in relapsed and/or refractory myeloma after at least 3 lines of treatment].
Croizier C; Van de Wyngaert Z
Bull Cancer; 2022 Feb; 109(2):113-114. PubMed ID: 35063182
[No Abstract] [Full Text] [Related]
49. Comparative Effectiveness Research for CAR-T Therapies in Multiple Myeloma: Appropriate Comparisons Require Careful Considerations of Data Sources and Patient Populations.
Shah N; Sussman M; Crivera C; Valluri S; Benner J; Jagannath S
Clin Drug Investig; 2021 Mar; 41(3):201-210. PubMed ID: 33598857
[TBL] [Abstract][Full Text] [Related]
50. Effect of granulocyte colony-stimulating factor on toxicities after CAR T cell therapy for lymphoma and myeloma.
Miller KC; Johnson PC; Abramson JS; Soumerai JD; Yee AJ; Branagan AR; O'Donnell EK; Saucier A; Jacobson CA; Frigault MJ; Raje NS
Blood Cancer J; 2022 Nov; 12(10):146. PubMed ID: 36316312
[TBL] [Abstract][Full Text] [Related]
51. Evaluating the Therapeutic Potential of Idecabtagene Vicleucel in the Treatment of Multiple Myeloma: Evidence to Date.
Mann H; Comenzo RL
Onco Targets Ther; 2022; 15():799-813. PubMed ID: 35912273
[TBL] [Abstract][Full Text] [Related]
52. The role of idecabtagene vicleucel in patients with heavily pretreated refractory multiple myeloma.
Oriol A; Abril L; Torrent A; Ibarra G; Ribera JM
Ther Adv Hematol; 2021; 12():20406207211019622. PubMed ID: 34104374
[TBL] [Abstract][Full Text] [Related]
53. Allogeneic CD34-selected stem cell boost as salvage treatment of life-threatening infection and severe cytopenias after CAR-T cell therapy.
de Tena PS; Bailén R; Oarbeascoa G; Gómez-Centurión I; Pérez-Corral A; Carbonell D; Martínez-Laperche C; Sancho M; Bastos-Oreiro M; Conde-Royo D; Fernández-Caldas P; Muñoz C; Sabell S; Buño I; Anguita J; Díez-Martín JL; Kwon M
Transfusion; 2022 Oct; 62(10):2143-2147. PubMed ID: 35986653
[TBL] [Abstract][Full Text] [Related]
54. Budget Impact Analysis of Idecabtagene Vicleucel for the Treatment of Adult Patients with Relapsed or Refractory Multiple Myeloma in the US.
Ghanem B; Shi L
Clin Drug Investig; 2022 Dec; 42(12):1085-1092. PubMed ID: 36316586
[TBL] [Abstract][Full Text] [Related]
55. Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma.
Raje N; Berdeja J; Lin Y; Siegel D; Jagannath S; Madduri D; Liedtke M; Rosenblatt J; Maus MV; Turka A; Lam LP; Morgan RA; Friedman K; Massaro M; Wang J; Russotti G; Yang Z; Campbell T; Hege K; Petrocca F; Quigley MT; Munshi N; Kochenderfer JN
N Engl J Med; 2019 May; 380(18):1726-1737. PubMed ID: 31042825
[TBL] [Abstract][Full Text] [Related]
56. Cytopenia after chimeric antigen receptor T cell immunotherapy in relapsed or refractory lymphoma.
Zhou J; Zhang Y; Shan M; Zong X; Geng H; Li J; Chen G; Yu L; Xu Y; Li C; Wu D
Front Immunol; 2022; 13():997589. PubMed ID: 36131934
[TBL] [Abstract][Full Text] [Related]
57. The efficacy of single-dose administration of thrombopoietin with coadministration of either granulocyte/macrophage or granulocyte colony-stimulating factor in myelosuppressed rhesus monkeys.
Neelis KJ; Hartong SC; Egeland T; Thomas GR; Eaton DL; Wagemaker G
Blood; 1997 Oct; 90(7):2565-73. PubMed ID: 9326222
[TBL] [Abstract][Full Text] [Related]
58. [CAR-T cells immunotherapy in multiple myeloma: Present and future].
Ferment B; Arnulf B
Bull Cancer; 2021 Oct; 108(10S):S65-S72. PubMed ID: 34920809
[TBL] [Abstract][Full Text] [Related]
59. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ
Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
[TBL] [Abstract][Full Text] [Related]
60. Intermittent granulocyte colony-stimulating factor for neutropenia management in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone.
Sun HL; Atenafu EG; Yeboah E; Reece DE; Trudel S; Kukreti V; Masih-Khan E; Winter A; Chen C
Leuk Lymphoma; 2015 Feb; 56(2):407-14. PubMed ID: 24738975
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
